The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …

Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with
coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe …

Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United
States, April–September 2022 - PMC Back to Top Skip to main content NIH NLM Logo Access …

Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …

Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …

The use of antiviral drugs represents an important progress in the therapeutic management
of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and …

Introduction The efficacy of molnupiravir (MLN) on Omicron sublineages is limited. We
investigated the effectiveness of MLN in older adults diagnosed with Omicron BA. 2 …